bit.bio

bit.bio is a synthetic biology company that uses its proprietary opti-ox™ technology to precisely, consistently and efficiently reprogram pluripotent stem cells into defined human cell types at scale. They supply off‑the‑shelf and bespoke iPSC‑derived cell products and services to support research, drug discovery, disease modelling and therapeutic development. bit.bio partners with pharma and biotech to accelerate target validation and cell therapy programs by delivering reproducible, well‑characterized human cells. Their platform emphasizes scalability and genetic control to replace variable primary cells and improve preclinical translational relevance.